Skip to main content
BMRN
NASDAQ Life Sciences

BioMarin 完成对 Amicus 的并购的最后法国外商投资审查，预计交易将于 4 月 27 日完成

feedReported by Wiseek News
Sentiment info
Positive
Importance info
8
Price
$53.91
Mkt Cap
$10.382B
52W Low
$50.76
52W High
$66.275
Market data snapshot near publication time

summarizeSummary

BioMarin Pharmaceutical Inc. 宣布已从法国经济和金融部获得对其与 Amicus Therapeutics 合并的最终外商直接投资清除。这一清除满足了最后的预关条件，合并现在预计将于 2026 年 4 月 27 日完成。BioMarin 以 48 亿美元收购 Amicus 是 2025 年年度报告中详细介绍的重要事件，本次更新消除了一个重大的监管障碍，从而降低了交易风险。这是 BioMarin 的一个重要发展，确认了一个重大战略收购的即将完成。投资者现在将关注交易的正式完成以及任何后续的整合计划或更新的财务指导。

在该公告发布时，BMRN的交易价格为$53.91，交易所为NASDAQ，所属行业为Life Sciences，市值约为$103.8亿。 52周交易区间为$50.76至$66.28。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed BMRN - Latest Insights

BMRN
Apr 27, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
9
BioMarin Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Secures $3.4 Billion in New Debt
Sentiment: Neutral
View Wiseek Article
BMRN
Apr 27, 2026, 8:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
BioMarin Officially Closes Amicus Therapeutics Acquisition
Sentiment: Neutral
View Wiseek Article
BMRN
Apr 23, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
BioMarin Clears Final French FDI Hurdle for Amicus Merger, Deal Expected to Close April 27
Sentiment: Positive
View Wiseek Article
BMRN
Apr 23, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
BioMarin Secures Final French FDI Clearance for Amicus Therapeutics Merger, Closing Expected April 27
Sentiment: Positive
View Wiseek Article
BMRN
Apr 21, 2026, 4:19 PM EDT
Filing Type: DEF 14A
Importance Score:
8
BioMarin Seeks Shareholder Approval for Significant Equity Plan Expansion and Board Leadership Transition
Sentiment: Negative
View Wiseek Article
BMRN
Mar 16, 2026, 8:38 AM EDT
Source: Reuters
Importance Score:
7
BioMarin Discontinues Multiple Voxzogo Phase 2 Trials Citing Adverse Events
Sentiment: Negative
View Wiseek Article
BMRN
Mar 16, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
BioMarin Halts VOXZOGO Phase 2 Trials for Multiple Indications Due to Safety Concerns
Sentiment: Negative
View Wiseek Article
BMRN
Feb 27, 2026, 8:02 PM EST
Source: Reuters
Importance Score:
7
FDA Expands BioMarin's Palynziq Approval to Adolescents with PKU
Sentiment: Positive
View Wiseek Article
BMRN
Feb 26, 2026, 12:30 PM EST
Filing Type: 10-K
Importance Score:
8
BioMarin Reports Full-Year 2025 Results, Details Amicus Acquisition, and ROCTAVIAN Withdrawal
Sentiment: Neutral
View Wiseek Article
BMRN
Feb 23, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
BioMarin Reports Mixed Q4/FY25 Results, Withdraws ROCTAVIAN, Issues Strong 2026 EPS Guidance
Sentiment: Neutral
View Wiseek Article